Eli Lilly and Company Aktie News

In addition to meeting the primary endpoint of non-inferiority for  overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to  78.5% for ibrutinib in the intent-to-treat (ITT) population Progression-free survival data were immature but trended in favor of pirtobrutinib with a 43% reduction of the risk of disease progression or d...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and some upcoming catalysts.

Lilly's market cap recently touched $1 trillion. Forecasts for the GLP-1 market are evolving.

Eli Lilly, Alphabet are among leading stocks in the IBD 50 list of growth stocks. Taiwan Semiconductor and AppLovin are near buy points.

Meta Platforms generates high cash flow and can afford to take risks on AI spending. ASML's lithography machines are essential for manufacturing advanced AI chips.

In this week's edition of InnovationRx, we look at the price cuts for blockbuster weight-loss drugs, the Forbes 30 Under 30 Healthcare list, the coming barriers to getting vaccines, and more. To get it in your inbox, subscribe here.

Eli Lilly has seen revenue soar thanks to its blockbuster weight loss drug portfolio. Lilly and Novo Nordisk dominate this market, which has seen high demand.

Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor This expanded indication represents a substantial increase in the number of CLL/SLL patients who may benefit from Jaypirca and aligns with the patient population endorsed by the NCCN Clinical Practice Guidelines in On...